Benefits
Ear, Nose, Throat (ENT) Health
BLIS K12 colonizes oral cavity and supports ENT health — clinical evidence for reduced recurrence of strep throat, ear infections, upper respiratory issues.
30+ Years Published Research
Robust clinical evidence base spanning three decades of research at multiple institutions.
Children and Adults Established Safety
Safe and effective for both children and adults — pediatric populations among most-studied for ENT applications.
BLIS Antimicrobial Production
Produces bacteriocin-like inhibitory substances (BLIS) — salivaricin A2 and B — that competitively inhibit harmful oral bacteria including Streptococcus pyogenes (strep throat).
Fresh Breath
Modulates oral microbiome reducing volatile sulfur compounds (VSCs) responsible for halitosis.
Natural Immune System Support
Supports natural immune defenses through oral cavity colonization and microbiome balance.
Dairy-Free Version Available
Recent dairy-free BLIS K12 (developed via Sacco System partnership) makes ingredient accessible to dairy-allergic populations.
Mechanism of action
Oral Cavity Colonization
S. salivarius K12 colonizes oral cavity (tongue, throat, palate) — competitive exclusion of pathogenic bacteria; establishes beneficial bacterial population.
Bacteriocin Production
Produces salivaricin A2 and salivaricin B — bacteriocin-like inhibitory substances that selectively kill or inhibit pathogenic streptococci, particularly Streptococcus pyogenes (strep throat).
Immune Modulation
Modulates oral cavity immune responses; supports innate immunity at mucosal surfaces.
Microbiome Rebalancing
Particularly effective after antibiotic therapy that disrupts oral microbiome — restores beneficial bacterial populations.
Clinical trials
Multiple BLIS K12 RCTs in children and adults with recurrent throat infections.
Children and adults with recurrent strep throat or pharyngotonsillitis.
Significantly reduced recurrence of strep throat infections; reduced antibiotic courses needed.
BLIS K12 pediatric trials for otitis media (ear infection) prevention.
Children with recurrent ear infections.
Reduced incidence of ear infections; supports pediatric ENT health.
About this ingredient
BLIS K12 is a PROPRIETARY STREPTOCOCCUS SALIVARIUS PROBIOTIC STRAIN developed by BLIS TECHNOLOGIES (New Zealand) — distributed by STRATUM NUTRITION in North America. STREPTOCOCCUS SALIVARIUS BACKGROUND: dominant beneficial organism in healthy oral cavity; specific strains produce bacteriocin-like inhibitory substances (BLIS); K12 is most-studied strain.
KEY DISTINCTIONS: (1) WORLD'S FIRST advanced oral probiotic; (2) 30+ YEARS published research; (3) PRODUCES BLIS (salivaricin A2 and B); (4) Clinical evidence in CHILDREN and ADULTS; (5) Dairy-free version now available; (6) USA patent numbers 6773912 and 7226590; (7) Distributed by Stratum Nutrition (ESM Technologies subsidiary).
EVIDENCE-BASED USES: (1) Ear, nose, throat (ENT) health; (2) Recurrent strep throat prevention; (3) Otitis media (ear infection) prevention in children; (4) Fresh breath; (5) Upper respiratory immune defense; (6) Post-antibiotic oral microbiome restoration.
CRITICAL CAUTIONS: (1) DAIRY ALLERGY — original version dairy-grown; dairy-free version now available; (2) IMMUNOCOMPROMISED — caution with live probiotics; rare bacteremia risk; consult; (3) ANTIBIOTICS — separate timing or use after antibiotic course; (4) CHILDREN — established pediatric safety and efficacy; primary use population; (5) DOSE — 1 billion CFU/day research-validated; (6) DURATION — typically 30-90 day courses; long-term use also studied; (7) DELIVERY FORMAT — typically lozenges or chewable tablets to allow oral cavity colonization; swallowed capsules less effective for ENT (ingredient bypasses target site); (8) BLIS K12 vs BLIS M18 — both Stratum Nutrition; K12 for ENT; M18 for teeth/gums; complementary; (9) BLIS K12 vs OTHER ORAL PROBIOTICS — K12 most-studied strain; specific clinical evidence for ENT applications; (10) FOR RECURRENT INFECTIONS — BLIS K12 for prevention; established infections still require appropriate medical treatment; (11) BRAND VERIFICATION — BLIS K12 is Blis Technologies trademark; distributed by Stratum Nutrition; specific patented strain.